Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Genetic testing can improve selection of women with ER positive breast cancer for ten rather than five years of hormonal therapy

Prof Mitch Dowsett - The Institute of Cancer Research, London, UK
Genetic testing can improve selection of women with ER positive breast cancer for ten rather than five years of hormonal therapy ( Prof Mitch Dowsett - The Institute of Cancer Research, London, UK )
1 Apr 2014

EBCC 2014 key messages to doctors

Prof David Cameron - Edinburgh Cancer Centre, Edinburgh, UK
EBCC 2014 key messages to doctors ( Prof David Cameron - Edinburgh Cancer Centre, Edinburgh, UK )
1 Apr 2014

Ganetespib in first-line treatment of women with metastatic HER2 positive or triple negative breast cancer

Prof David Cameron - Edinburgh Cancer Centre, Edinburgh, UK
Ganetespib in first-line treatment of women with metastatic HER2 positive or triple negative breast cancer ( Prof David Cameron - Edinburgh Cancer Centre, Edinburgh, UK )
1 Apr 2014

The future of mCRPC treatment - expert discussion

Prof Li Ping Xie - Zhejiang University School of Medicine, Hangzhou, China and Prof Paul de Souza - University of Western Sydney, Sydney, Australia
The future of mCRPC treatment - expert discussion ( Prof Li Ping Xie - Zhejiang University School of Medicine, Hangzhou, China and Prof Paul de Souza - University of Western Sydney, Sydney, Australia )
21 Mar 2014

mCRPC management in Taiwan - expert interview

Prof Paul de Souza and Dr Wayne Yen-Hwa Chang
mCRPC management in Taiwan - expert interview ( Prof Paul de Souza and Dr Wayne Yen-Hwa Chang )
21 Mar 2014

PSA as a marker of disease in patients with prostate cancer and bone metastases

Prof Laurence Koltz, Prof Wolfgang Horninger, Prof Bertrand Tombal
PSA as a marker of disease in patients with prostate cancer and bone metastases ( Prof Laurence Koltz, Prof Wolfgang Horninger, Prof Bertrand Tombal )
28 Feb 2014

Predictive power of PSA patterns during off-time treatment periods with intermittent androgen deprivation

Dr Rafael Sanchez-Salas - Institut Mutualiste Montsouris, Paris, France
Predictive power of PSA patterns during off-time treatment periods with intermittent androgen deprivation ( Dr Rafael Sanchez-Salas - Institut Mutualiste Montsouris, Paris, France )
1 Feb 2014

MET variant as a prognostic marker in clear cell renal cell carcinoma

Dr Ari Hakimi - Memorial Sloan-Kettering Cancer Center, New York, USA
MET variant as a prognostic marker in clear cell renal cell carcinoma ( Dr Ari Hakimi - Memorial Sloan-Kettering Cancer Center, New York, USA )
31 Jan 2014

Enzalutamide improves survival in men with metastatic castration-resistant prostate cancer

Dr Tomasz M. Beer - Oregon Health & Science University, Portland, USA
Enzalutamide improves survival in men with metastatic castration-resistant prostate cancer ( Dr Tomasz M. Beer - Oregon Health & Science University, Portland, USA )
31 Jan 2014

Dissecting the biology of the androgen receptor pathway

Dr Peter Nelson - Fred Hutchinson Cancer Research Center, Seattle, USA
Dissecting the biology of the androgen receptor pathway ( Dr Peter Nelson - Fred Hutchinson Cancer Research Center, Seattle, USA )
30 Jan 2014

HER2 positive breast cancer treatment, past and future

Dr Edith Perez - Mayo Clinic, Rochester, USA
HER2 positive breast cancer treatment, past and future ( Dr Edith Perez - Mayo Clinic, Rochester, USA )
19 Dec 2013

Breast cancer psychosocial and survivorship issues: are we doing better?

Dr Lesley Fallowfield - University of Sussex, Brighton, UK
Breast cancer psychosocial and survivorship issues: are we doing better? ( Dr Lesley Fallowfield - University of Sussex, Brighton, UK )
19 Dec 2013